FIMECS, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
FIMECS, Inc. - overview
Established
2018
Location
Fujisawa-shi, Kanagawa, Japan
Primary Industry
Biotechnology
About
Based in Kanagawa, Japan, and founded in 2018 by co-founders Yusuke Tominari, Ph. D. (CEO), Yusuke Kohno, Kanae Gamo, Ph. D.
, and Yoshihide Tomata, Ph. D. , FIMECS, Inc. operates as a provider of targeted protein degradation drug discovery solutions to global pharmaceutical companies focusing on immuno-oncology and oncology research.
In February 2024, RaQualia Pharma Inc. acquired FIMECS from Nissay Capital, ANRI, UTokyo Innovation Platform, and Kyoto University Innovation Capital for JPY 4. 5 billion. The company provides a wide range of drug discovery solutions using proprietary E3 ligase binders and the RaPPIDS platform for the degradation of disease-relevant proteins.
Current Investors
Takeda Pharmaceutical, ANRI, Kyoto University Innovation Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Healthcare IT, Oncology/Cancer Treatment
Website
www.fimecs.com/
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.